- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Helping Patients With Metastatic Breast Cancer Enroll in Clinical Trials
Sonya Negley, IOM, CSMA, describes the patient advocate’s role in helping patients with metastatic breast cancer discover and enroll in clinical trials.
EP: 1.Differences Between SERDs and Other Therapies
EP: 2.Efficacy of Oral SERDs in the EMERALD Trial
EP: 3.Safety Concerns Associated With Oral SERDs
EP: 4.Benefits of Using Oral SERDs
EP: 5.Progression-Free Survival of Oral SERDs in Clinical Practice
EP: 6.Role of Oral SERDs in Treatment of ER+/HER2- in Metastatic Breast Cancer
EP: 7.ESR1 Mutation Confirmation With Oral SERDs
EP: 8.Coverage Considerations for Oral SERDs
EP: 9.Clinical Impact of Oral SERDs
EP: 10.Treatment Failure and Resistance Before Oral SERDs
EP: 11.Cardiovascular Risk and Menopausal Symptoms Associated With Oral SERDs
EP: 12.Monitoring and Managing Adverse Effects With Oral SERDs
EP: 13.Payer Perspectives on SERDs
EP: 14.Ensuring Access to Oral SERDs
EP: 15.How Patient Advocates Can Help the Newly Diagnosed
EP: 16.Empowering Patients With Metastatic Breast Cancer
EP: 17.Helping Patients With Metastatic Breast Cancer Enroll in Clinical Trials
EP: 18.Guiding Patients Through Complex Treatment Decisions
EP: 19.Patient Advocate's Role in Shared Decision Making
EP: 20.Helping Patients Overcome Health Disparities as a Patient Advocate
Sonya Negley, IOM, CSMA: I think there are a few things we can do as organizations. We can make sure we are educating patients about what is available in clinical trials, and we as patient advocacy organizations need to look at it comprehensively, not just trials that may or may not be on clinicaltrials.gov, but clinical trials in general, and how can those trials support the patient? I think we have to be very cautious that it’s not the patient’s work to go out and make sure all of the trials have patients involved or that type of thing. But more so, giving their input in the way they feel they can best share their voice.
We want people who are living with metastatic breast cancer to feel like they are doing everything in their life that they want to do. Their lives are shortened, and it is incredibly important that they spend time with their loved ones. And it’s important for all of us to remember, whether we’re in research, science, or in patient advocacy, that people’s time that we’re using is time they’re taking away from their loved ones. So, [we need to] be efficient in making sure their goals are met, and [understanding] it’s a very important task, and [helping patients realize] that their participation is going to reward them personally, as well as rewarding discovery in this space.
Transcript edited for clarity.
Age-Related Disparities in Long-Term Outcomes for ER+, HER2– Breast Cancer
November 23rd 2024Younger women with estrogen receptor (ER)–positive, HER2-negative breast cancer have significantly worse long-term outcomes, including higher rates of recurrence and metastasis, compared with older women.
Read More
Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening
October 30th 2023On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.
Listen
Breast Cancer Outcomes Improved in States With Medicaid Expansion
October 24th 2024Medicaid expansion is associated with improved care and increased survival rates for patients with certain breast cancers, but future studies should focus on whether Medicaid expansion mitigates the disparities between Black and non-White patients.
Read More
The Disproportionate Impact of the Pandemic on Health Care Disparities and Cancer
February 22nd 2022On this episode of Managed Care Cast, we discuss how already wide health care inequities in cancer are becoming much worse because of the COVID-19 pandemic, with guest Monica Soni, MD, associate chief medical officer at New Century Health.
Listen
Advancing Breast Cancer Care With HER2-Targeted Therapies
October 10th 2024In this interview from our Institute for Value-Based Medicine® event in Boston, we speak with Michael Hassett, MD, MPH, Dana-Farber Cancer Institute, on the clinical significance and cost implications of HER2 in the breast cancer space.
Read More
